NEPHROCARE HEALTH SERV L
NEPHROPLUS · General/Diversified · NSE
₹534
Current Market Price
Fair Value (DCF)
₹182
Margin of Safety
-65.8%
Updated just now
YieldIQ Score
67/100
Piotroski F-Score
8/9
Economic Moat
Narrow
Confidence
26%
ROE
—
Debt/Equity
0.36
WACC
11.1%
Market Cap
₹5,354 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
22.9×
Enterprise multiple
Debt / EBITDA
1.2×
Leverage vs earnings
Interest Coverage
—
EBIT covers interest
Current Ratio
—
Short-term liquidity
Asset Turnover
0.75×
Revenue per ₹ of assets
Revenue CAGR (3Y)
16.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹533.55
Bear case
₹108.21
MoS -393.1%
Base case
₹182.3
MoS -192.7%
Bull case
₹229.01
MoS -133.0%
Ratio Trends
NEPHROPLUS · last 4 annual periods
ROE
11.5%
ROCE
21.2%
Operating Margin
—
Debt / Equity
0.44×
PE
—
EV / EBITDA
—
Historical Financials
NEPHROPLUS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹474 Cr | ₹415 Cr | ₹540 Cr | ₹748 Cr | +16.5% |
| EBITDA | ₹122 Cr | ₹52.9 Cr | ₹107 Cr | ₹179 Cr | +13.6% |
| EBIT | — | — | — | — | — |
| PAT | ₹14.2 Cr | ₹-11.8 Cr | ₹35.1 Cr | ₹67.1 Cr | +67.7% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹38.1 Cr | ₹11.3 Cr | ₹72.3 Cr | ₹135 Cr | +52.6% |
| CapEx | ₹-61.3 Cr | ₹-73.7 Cr | ₹-80.0 Cr | ₹-101 Cr | — |
| FCF | ₹-23.2 Cr | ₹-62.5 Cr | ₹-7.7 Cr | ₹34.5 Cr | — |
| Total Assets | ₹1194 Cr | ₹666 Cr | ₹806 Cr | ₹996 Cr | -5.8% |
| Total Debt | ₹261 Cr | ₹214 Cr | ₹268 Cr | ₹258 Cr | -0.5% |
| Shareholders' Equity | ₹717 Cr | ₹389 Cr | ₹414 Cr | ₹584 Cr | -6.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NEPHROPLUS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| YATHARTH YATHARTH HOSP & TRA C S L | -0.3% | 58 | Near Fair Value | 8.0% | — |
| JLHL JLHL | — | — | Pending | 14.3% | — |
| HCG HCG | — | — | Pending | 4.5% | — |
| JSLL JEENA SIKHO LIFECARE LTD | -38.5% | 51 | Above Fair Value | 33.2% | — |
| PARKHOSPS PARKHOSPS | — | — | Pending | 18.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NEPHROPLUS in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NEPHROPLUS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NEPHROPLUS →
Compare
Head-to-head with peers
Compare NEPHROPLUS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NEPHROPLUSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.